Compare GRF & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | ATNM |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.0M | 36.8M |
| IPO Year | N/A | 2013 |
| Metric | GRF | ATNM |
|---|---|---|
| Price | $10.20 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 1.9K | ★ 237.7K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $9.50 | $0.95 |
| 52 Week High | $11.85 | $1.95 |
| Indicator | GRF | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 56.57 |
| Support Level | $9.60 | $1.28 |
| Resistance Level | $10.61 | $1.56 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 63.76 | 44.11 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.